JAK1 and congenital rubella syndrome: Several studies have found that the use of small molecule inhibitors, including ruxolitinib (an inhibitor of Janus kinases 1 and 2) and itacitinib (a selective Janus kinase 1 inhibitor), may also help prevent CRS induced by CAR T-cell therapy (Huarte et al., 2020; Pan et al., 2021; Xu et al., 2022).